AlcaSynn Pharmaceuticals Overview

  • Year Founded
  • 2002

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 1

AlcaSynn Pharmaceuticals General Information

Description

Operator of a drug development company intended to focus on the preclinical and clinical development of morphinan opioids. The company's products are based on synthetic morphinane derivatives with a pronounced pharmacological effect in the treatment of pain, inflammation, Parkinson's and Alzheimer's.

Contact Information

Website
www.alcasynn.com
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Life Science Center
  • Mitterweg 24
  • Innsbruck, 6020
  • Austria
Primary Industry
Drug Discovery
Acquirer
Sanochemia Pharmazeutika
Corporate Office
  • Life Science Center
  • Mitterweg 24
  • Innsbruck, 6020
  • Austria

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AlcaSynn Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore AlcaSynn Pharmaceuticals‘s full profile, request access.

Request a free trial

AlcaSynn Pharmaceuticals Patents

  • 29

    Total Documents Applications and Grants

  • Total Patents Families

  • 7

    Granted

  • 1

    Pending

  • Expiring in next 12 mo

AlcaSynn Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20130281698-A1 Novel 6-amino-morphinan derivatives, method of manufacturing them and their application as analgesics Inactive 12-Sep-2005
EP-1762569-A1 Novel 6-amino-morphinan derivatives, method of manufacturing them and their application as analgesics Inactive 12-Sep-2005
AU-2005239831-A1 Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin Inactive 12-May-2004
ES-2334042-T3 Use of antagonist compounds of operative receptors for the prevention and / or treatment of diseases associated with calcineurine as a diana. Inactive 12-May-2004
EP-1755604-A2 Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin Active 12-May-2004 A61K31/485
To view AlcaSynn Pharmaceuticals’s complete patent history, request access »

AlcaSynn Pharmaceuticals FAQs

  • When was AlcaSynn Pharmaceuticals founded?

    AlcaSynn Pharmaceuticals was founded in 2002.

  • Where is AlcaSynn Pharmaceuticals headquartered?

    AlcaSynn Pharmaceuticals is headquartered in Innsbruck, Austria.

  • What industry is AlcaSynn Pharmaceuticals in?

    AlcaSynn Pharmaceuticals’s primary industry is Drug Discovery.

  • Is AlcaSynn Pharmaceuticals a private or public company?

    AlcaSynn Pharmaceuticals is a Private company.

  • What is the current valuation of AlcaSynn Pharmaceuticals?

    The current valuation of AlcaSynn Pharmaceuticals is .

  • What is AlcaSynn Pharmaceuticals’s current revenue?

    The current revenue for AlcaSynn Pharmaceuticals is .

  • When was AlcaSynn Pharmaceuticals acquired?

    AlcaSynn Pharmaceuticals was acquired on 09-Jun-2006.

  • Who acquired AlcaSynn Pharmaceuticals?

    AlcaSynn Pharmaceuticals was acquired by Sanochemia Pharmazeutika.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »